Study of safusidenib for grade 2 IDH1-mutant glioma
Part of Cancer clinical trials.
This trial tests a drug called safusidenib in people with a slow-growing brain tumor (grade 2 glioma) that has a specific IDH1 gene mutation. The goal is to see if the drug can help control the tumor without needing chemotherapy or radiation right away.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a grade 2 glioma with an IDH1 mutation and have had at least one surgery for it.
- Your last surgery was between 90 days and 5 years ago (or 28 days for a biopsy).
- You have not had any other cancer treatment besides surgery for your glioma.
- You do not need chemotherapy or radiation right now, in your doctor's opinion.
- Your tumor is measurable and not enhancing on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests safusidenib, a targeted medicine, to help stop or slow the return of certain brain tumors with an IDH1 mutation. It focuses on people after initial treatment (surgery and/or radiation and temozolomide), aiming to improve outcomes during maintenance therapy.
This study tests a new drug called safusidenib for people with IDH1-mutant gliomas (a type of brain tumor) that kept growing even while on the previous drug vorasidenib. The goal is to see if it can control the tumor safely and effectively.
This trial tests a combination of two oral medications, olutasidenib and temozolomide, for people with a specific type of aggressive brain tumor (high-grade glioma) that has an IDH1 mutation. The goal is to see if this combination can help control the tumor after standard treatment like radiation.
This Phase 2 study tests a combination of chemotherapy and radiation after surgery for certain brain tumors that are “IDH wildtype.” It aims to control the tumor and improve outcomes for people with specific types of glioma or glioblastoma.
This Phase 1/2 trial tests a study treatment for children and young adults under 22 whose brain glioma has come back or isn’t responding to prior treatment. It’s designed to see whether the treatment is safe and effective for shrinking tumors in this situation.
This trial tests the drug vorasidenib for people with a slow-growing brain tumor (Grade 2 glioma) that has an IDH mutation. The goal is to see how well the drug works and how it affects your quality of life.
Hear when a new Astrocytoma, IDH-Mutant, Grade 2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.